Skip to main content

Clinical Trials Using Bevacizumab

Review the clinical trials studying bevacizumab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 76-100 of 117

A Clinical Study of MK-1084 With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
Status: Active
Location: 3 locations
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
Status: Active
Location: Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York
Autophagy Maintenance Therapy (Hydroxychloroquine and Nelfinavir) plus Bevacizumab for the Treatment of Recurrent High-Grade Serous Ovarian, Fallopian Tube, and Primary Peritoneal Cancer, AUTOMAIN Trial
Status: Active
Location: Medical University of South Carolina, Charleston, South Carolina
APL-2 and Pembrolizumab versus APL-2, Pembrolizumab and Bevacizumab versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
BMS-986340, Nivolumab, Trifluridine/Tipiracil and Bevacizumab for the Treatment of Refractory, Microsatellite-Stable, Locally Advanced, Unresectable or Metastatic Colorectal Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Atezolizumab and Bevacizumab with Y90 Radioembolization for the Preparation for Liver Transplantation for Patients with Hepatocellular Carcinoma
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
Botensilimab and Balstilimab with Combination Chemotherapy for the Treatment of Patients with Metastatic Microsatellite Stable Colorectal Cancer
Status: Active
Location: Duke University Medical Center, Durham, North Carolina
Carboplatin, Paclitaxel, and Pembrolizumab Before Surgery Followed by Olaparib and Pembrolizumab with or without Bevacizumab for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Antiangiogenic Therapy for Children with Recurrent Medulloblastoma, Ependymoma and ATRT
Status: Active
Location: Medical University of South Carolina, Charleston, South Carolina
Radiation Treatment (Therasphere) in Combination with Systemic Therapy for the Treatment of Advanced Hepatocellular Carcinoma
Status: Active
Location: Northwestern University, Chicago, Illinois
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined with Immune Checkpoint Inhibition after High-Dose External Beam Radiation Therapy in Treating Patients with Unresectable Liver Cancer
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
A Study of GSK5733584 in Combination With Anti-cancer Therapies for Advanced Solid Tumors
Status: Active
Location: 2 locations
Valemetostat Tosylate with Atezolizumab and Bevacizumab for the Treatment of Locally Advanced, Unresectable or Metastatic Hepatocellular Carcinoma
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
External Beam Radiation Therapy and Brachytherapy with Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer
Status: Active
Location: 5 locations
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Status: Active
Location: USC / Norris Comprehensive Cancer Center, Los Angeles, California
Pemigatinib and Atezolizumab With or Without Bevacizumab for Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Lurbinectedin in Combination with Paclitaxel and Bevacizumab for the Treatment of Patients with Platinum-Resistant or Platinum-Refractory Ovarian Cancers
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
ProAgio with Fluorouracil, Irinotecan, and Bevacizumab for the Treatment of Advanced or Metastatic Colorectal Cancer
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Combination Chemotherapy and Bevacizumab with the NovoTTF-100L/ NovoTTF-200T System in Treating Patients with Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
IACS-6274 with or without Bevacizumab and Paclitaxel or Capivasertib for the Treatment of Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
CBP-1019 with FOLFOX with or without Bevacizumab, Pembrolizumab, or Enzalutamide for the Treatment of Metastatic Solid Tumors of Epithelial Origin
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Spectroscopic MRI-Guided Proton Radiation Therapy and Bevacizumab for the Treatment of Recurrent Glioblastoma
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Circulating Tumor DNA for Risk Determination and Treatment Selection in Patients with Carcinomatosis from Colorectal or Appendiceal Adenocarcinoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas